ArticleHealth research policy and systems2018
Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes.
Article in Health research policy and systems, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment.Health research policy and systems · 2021Pooled it
- The impact paradox: mixed-methods evaluation of National Institute of Health and Care Research funding for intellectual disability research in the UK.BJPsych open · 2026Article
- Sustaining physical activity following participation in a joint pain exercise and education rehabilitation programme; a qualitative longitudinal study.Frontiers in psychology · 2026Article
- Cauda Equina Syndrome: A Survey of Guideline Utilisation in Primary Care in England.Musculoskeletal care · 2025Article
- Is there a sufficient supply of clinical academics for UK medical schools? A retrospective cohort study.BMJ open · 2024Article
- Can the sustainable development goal 9 support an untreated early childhood caries elimination agenda?BMC oral health · 2024Review
- Quantifying public and private investment in European biopharmaceutical research and development.Health affairs scholar · 2024Article
- Brazil must complete the cycle in vaccine development.Cadernos de saude publica · 2024Article
- The BSSO Foundry: A community of practice for ontologies in the behavioural and social sciences.Wellcome open research · 2024Article
- ESSKA consensus initiative: why, when and how?Journal of experimental orthopaedics · 2023Review
- An assessment of the performance of the national health research system in Mauritius.BMC health services research · 2023Review
- What funders are doing to assess the impact of their investments in health and biomedical research.Health research policy and systems · 2022Review
- An NIH investment in health equity - the economic impact of the Flint Center for Health Equity Solutions.BMC public health · 2021Article
- Counting publications and citations is not just irrelevant: it is an incentive that subverts the impact of clinical research.British journal of sports medicine · 2021Article
- Are UK and Ireland trauma and orthopaedic surgeons maintaining their research output?Annals of the Royal College of Surgeons of England · 2020Article
- Transforming the practice of medicine through team science.Health research policy and systems · 2020Article
- From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?Health research policy and systems · 2020Article
- Evolving Trends in Physiotherapy Research Publications between 1995 and 2015.Physiotherapy Canada. Physiotherapie Canada · 2020Article
- Health research systems in change: the case of 'Push the Pace' in the National Institute for Health Research.Health research policy and systems · 2019Article
- Economic returns to medical research funding.BMJ open · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBuilding on an approach applied to cardiovascular and cancer research, we estimated the economic returns from United Kingdom public- and charitable-funded musculoskeletal disease (MSD) research that arise from the net value of the improved health outcomes in the United Kingdom.
methodsTo calculate the economic returns from MSD-related research in the United Kingdom, we estimated (1) the public and charitable expenditure on MSD-related research in the United Kingdom between 1970 and 2013; (2) the net monetary benefit (NMB), derived from the health benefit in quality adjusted life years (QALYs) valued in monetary terms (using a base-case value of a QALY of £25,000) minus the cost of delivering that benefit, for a prioritised list of interventions from 1994 to 2013; (3) the proportion of NMB attributable to United Kingdom research; and (4) the elapsed time between research funding and health gain. The data collected from these four key elements were used to estimate the internal rate of return (IRR) from MSD-related research investments on health benefits. We analysed the uncertainties in the IRR estimate using a one-way sensitivity analysis.
resultsExpressed in 2013 prices, total expenditure on MSD-related research from 1970 to 2013 was £3.5 billion, and for the period used to estimate the rate of return, 1978-1997, was £1.4 billion. Over the period 1994-2013 the key interventions analysed produced 871,000 QALYs with a NMB of £16 billion, allowing for the net NHS costs resulting from them and valuing a QALY at £25,000. The proportion of benefit attributable to United Kingdom research was 30% and the elapsed time between funding and impact of MSD treatments was 16 years. Our best estimate of the IRR from MSD-related research was 7%, which is similar to the 9% for CVD and 10% for cancer research.
conclusionsOur estimate of the IRR from the net health gain to public and charitable funding of MSD-related research in the United Kingdom is substantial, and justifies the research investments made between 1978 and 1997. We also demonstrated the applicability of the approach previously used in assessing the returns from cardiovascular and cancer research. Inevitably, with a study of this kind, there are a number of important assumptions and caveats that we highlight, and these can inform future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.